A Research Study to See if Kidney Damage in People With Chronic Kidney Disease and Type 2 Diabetes Living With Overweight or Obesity Can be Reduced by CagriSema Compared to Semaglutide, Cagrilintide and Placebo
NCT ID: NCT06131372
Last Updated: 2025-11-28
Study Results
The study team has not published outcome measurements, participant flow, or safety data for this trial yet. Check back later for updates.
Basic Information
Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.
COMPLETED
PHASE2
626 participants
INTERVENTIONAL
2024-04-01
2025-11-06
Brief Summary
Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.
Related Clinical Trials
Explore similar clinical trials based on study characteristics and research focus.
Visceral Adipose Tissue and Liver Changes Associated With Semaglutide in CKD
NCT07187830
A Research Study Comparing How Well Different Doses of the Medicine NNC0519-0130 Can Reduce Kidney Damage in People Living With Chronic Kidney Disease
NCT06717698
SeMaglutide and Albuminuria Reduction Trial in Obese Individuals Without Diabetes
NCT04889183
A Research Study to Find Out How Semaglutide Works in the Kidneys Compared to Placebo, in People With Type 2 Diabetes and Chronic Kidney Disease (the REMODEL Trial)
NCT04865770
A Research Study to See How Semaglutide Works Compared to Placebo in People With Type 2 Diabetes and Chronic Kidney Disease
NCT03819153
Detailed Description
Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.
Conditions
See the medical conditions and disease areas that this research is targeting or investigating.
Study Design
Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.
RANDOMIZED
PARALLEL
TREATMENT
QUADRUPLE
Study Groups
Review each arm or cohort in the study, along with the interventions and objectives associated with them.
CagriSema
Participants will receive cagrilintide and semaglutide subcutaneously once-weekly after a dose escalation period of 16 weeks during the maintenance period for 10 weeks.
Cagrilintide
Participants will receive Cagrilintide subcutaneously.
Semaglutide
Participants will receive semaglutide subcutaneously.
Semaglutide
Participants will receive semaglutide and placebo matched to cagrilintide subcutaneously once-weekly after a dose escalation period of 16 weeks during the maintenance period for 10 weeks.
Semaglutide
Participants will receive semaglutide subcutaneously.
Placebo
Participants will receive placebo matched to cagrilintide or placebo matched to semaglutide subcutaneously.
Cagrilintide
Participants will receive cagrilintide and placebo matching to semaglutide subcutaneously once-weekly after a dose escalation period of 16 weeks during the maintenance period for 10 weeks.
Cagrilintide
Participants will receive Cagrilintide subcutaneously.
Placebo
Participants will receive placebo matched to cagrilintide or placebo matched to semaglutide subcutaneously.
Placebo
Participants will receive placebo matched to cagrilintide and placebo matched to semaglutide subcutaneously once weekly for 26 weeks.
Placebo
Participants will receive placebo matched to cagrilintide or placebo matched to semaglutide subcutaneously.
Interventions
Learn about the drugs, procedures, or behavioral strategies being tested and how they are applied within this trial.
Cagrilintide
Participants will receive Cagrilintide subcutaneously.
Semaglutide
Participants will receive semaglutide subcutaneously.
Placebo
Participants will receive placebo matched to cagrilintide or placebo matched to semaglutide subcutaneously.
Eligibility Criteria
Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.
Inclusion Criteria
* Age 18 years or above at the time of signing the informed consent.
* Diagnosed with type 2 diabetes mellitus ≥ 180 days before screening.
* Body mass index (BMI) ≥ 27.0 kilograms per meter square (kg/m\^2) at screening. BMI will be calculated in the eCRF (electronic case report form) based on height and body weight at screening.
* HbA1c less than or equal to (≤) 10.5% (91 millimoles per mole \[mmol/mol\]) as assessed by central laboratory at screening.
* Kidney impairment defined by serum creatinine and cystatin C-based eGFR ≥ 15 and \< 90 milliliters per minutes per 1.73\^m\^2 (mL/min/1.73 m\^2) (CKD-EPI 2021) as assessed by central laboratory at screening.
* Albuminuria defined by UACR ≥ 100 and \< 5000 milligram per gram (mg/g) as assessed by central laboratory at screening.
* Treatment with maximum labelled or tolerated dose of an angiotensin converting enzyme (ACE) inhibitor or an angiotensin II receptor blocker (ARB), unless such treatment is contraindicated or not tolerated, in the opinion of the investigator. Treatment dose must be stable for at least 30 days prior to screening.
Exclusion Criteria
* Congenital or hereditary kidney diseases including polycystic kidney disease, autoimmune kidney diseases including glomerulonephritis or congenital urinary tract malformations.
* Use of any glucagon-like peptide-1 receptor agonist (GLP-1RA) (including medication with GLP-1RA activity, e.g., GIP/GLP-1RA) or amylin analogue within 60 days prior to screening.
* Myocardial infarction, stroke, transient ischaemic attack, or hospitalization for unstable angina pectoris within 60 days before screening.
* Chronic or intermittent haemodialysis or peritoneal dialysis within 90 days before screening.
* Uncontrolled and potentially unstable diabetic retinopathy or maculopathy. Verified by an eye examination performed within 90 days before screening or in the period between screening and randomisation. Pharmacological pupil-dilation is a requirement unless using a digital fundus photography camera specified for non-dilated examination.
* Presence or history of malignant neoplasms or in situ carcinomas (other than basal or squamous cell skin cancer, low-risk prostate cancer, or in-situ carcinomas of the cervix or carcinoma in situ/high grade prostatic intraepithelial neoplasia (PIN) within 5 years before screening.
18 Years
ALL
No
Sponsors
Meet the organizations funding or collaborating on the study and learn about their roles.
Novo Nordisk A/S
INDUSTRY
Responsible Party
Identify the individual or organization who holds primary responsibility for the study information submitted to regulators.
Principal Investigators
Learn about the lead researchers overseeing the trial and their institutional affiliations.
Clinical Transparency (dept. 2834)
Role: STUDY_DIRECTOR
Novo Nordisk A/S
Locations
Explore where the study is taking place and check the recruitment status at each participating site.
John Muir Physicians Network
Concord, California, United States
Valley Research
Fresno, California, United States
Desert Oasis Hlthcr Med Group
Palm Springs, California, United States
North America Research Institute
San Dimas, California, United States
NorCal Endocrinology and Internal Medicine
San Ramon, California, United States
Northeast Research Institute
Fleming Island, Florida, United States
Life Spring Research
Miami, Florida, United States
Florida Hospital Translational Research Institute
Orlando, Florida, United States
Velocity Clin. Res Valparaiso
Valparaiso, Indiana, United States
Elite Research Center
Flint, Michigan, United States
Univ. of Nebraska Medical Center_Omaha
Omaha, Nebraska, United States
Albany Medical College
Albany, New York, United States
NYU Langone Neph Associates
Mineola, New York, United States
New York University School of Medicine
New York, New York, United States
Southgate Medical Group, LLP
West Seneca, New York, United States
Carteret Medical Group
Morehead City, North Carolina, United States
Eastern Nephr Assoc, PLLC
New Bern, North Carolina, United States
Brookview Hills Research Associates, LLC
Winston-Salem, North Carolina, United States
Ohio- Advanced Medical Research
Maumee, Ohio, United States
Heritage Valley Medical Group Inc
Beaver, Pennsylvania, United States
Main Street Physician's Care
Little River, South Carolina, United States
Osvaldo A. Brusco MD PA
Corpus Christi, Texas, United States
Southwest Houston Research Ltd
Houston, Texas, United States
Clinical Advancement Ctr, PLLC
San Antonio, Texas, United States
Clinical Investigation Spec. Kenosha
Kenosha, Wisconsin, United States
Mautalen Salud e investigación
CABA, Buenos Aires, Argentina
Centro de Investigaciones Médicas Mar del Plata
Mar del Plata, Buenos Aires, Argentina
Fundación CESIM
Santa Rosa, La Pampa Province, Argentina
Centro Medico Dra. Laura Maffei e Investigacion Clínica Apli
Buenos Aires, , Argentina
Centro Médico Privado San Vicente Diabetes
Córdoba, , Argentina
Instituto Pró-Renal Brasil
Curitiba, Paraná, Brazil
Núcleo de Pesquisa Clínica do Rio Grande do Sul Ltda.
Porto Alegre, Rio Grande do Sul, Brazil
CPCLIN - Centro de Pesquisas Clínicas
São Paulo, São Paulo, Brazil
Hospital do Rim e Hipertensao Fundacao Oswaldo Ramos
São Paulo, , Brazil
Centricity Research Calgary
Calgary, Alberta, Canada
Centricity Research Brampton
Brampton, Ontario, Canada
Centricity Research Vaughn Endocrinology
Concord, Ontario, Canada
Centricity Research Etobicoke
Etobicoke, Ontario, Canada
Hamilton Medical Rsrch Grp
Hamilton, Ontario, Canada
Bluewater Clin Res Group Inc
Sarnia, Ontario, Canada
UHN-Toronto General Hospital
Toronto, Ontario, Canada
Ctr de rech Clin de Laval
Laval, Quebec, Canada
Centre Medical Acadie
Montreal, Quebec, Canada
Groupe Sos Sante-Hopital Le Creusot-Hotel Dieu-1
Le Creusot, , France
Gie Groupe Hospitalier Paris Saint-Joseph/Vinci
Paris, , France
Centre Hospitalier Universitaire de Poitiers
Poitiers, , France
Centre Hospitalier Universitaire Reims-Hopital Maison Blanche
Reims, , France
Centre Hospitalier Universitaire de Nantes-Hopital Nord Laennec-1
Saint-Herblain, , France
Centre Hospitalier Universitaire de Toulouse-Hopital Rangueil-1
Toulouse, , France
Centre de Recherche Clinique Portes Du Sud
Vénissieux, , France
University General Hospital Of Heraklion
Heraklion, Crete, Greece
"Laiko" General Hospital of Athens
Athens, , Greece
Gen Hospital of Athens Laiko,1st Dpt. of Propaedeutic Inter
Athens, , Greece
General hospital of Athens 'G.Gennimatas'
Athens, , Greece
Iatriko Athinon 'Palaiou Falirou'
Athens, , Greece
"Laiko" General Hospital of Athens
Athens, , Greece
Gen Hospital of Athens Laiko,1st Dpt. of Propaedeutic Inter
Athens, , Greece
General hospital of Athens 'G.Gennimatas'
Athens, , Greece
General Hospital of Lamia
Lamia, , Greece
Univ Gen Hospital Larisa
Larissa, , Greece
Univ Gen Hospital Larisa, Endocrinology & Metabolic Disease
Larissa, , Greece
General University Hospital of Patras,Nephrology clinic
Pátrai, , Greece
General University Hospital of Patras,Nephrology clinic
Rio, Patra, , Greece
General Hospital of Thessaloniki 'G. Gennimatas
Thessaloniki, , Greece
"Ippokrateio" G.H. of Thessaloniki
Thessaloniki, , Greece
General Hospital of Thessaloniki "Ippokrateio"
Thessaloniki, , Greece
General Hospital of Thessaloniki "G.Papanikolaou"
Thessaloniki, , Greece
General Hospital of Thessaloniki 'G. Gennimatas
Thessaloniki, , Greece
"Ippokrateio" G.H. of Thessaloniki
Thessaloniki, , Greece
General Hospital of Thessaloniki "G.Papanikolaou"
Thessaloniki, , Greece
PTE-AOK II. Belgyogyaszati Klinika es Nephrologiai Centrum
Pécs, Baranya Vármegye, Hungary
Lausmed Kft.
Baja, Bács-Kiskun county, Hungary
Belinus Bt.
Debrecen, Hajdú-Bihar, Hungary
Siófoki Kórház, Diabetológiai Szakrendelés
Siófok, Somogy County, Hungary
Borbánya Praxis E.Ü. Kft.
Nyíregyháza, Szabolcs-Szatmar Varmegye, Hungary
Szent Margit Rendelőintézet Nonprofit Kft.
Budapest, , Hungary
Békés Megyei Központi Kórház
Gyula, , Hungary
Endolife Specialty Hospitals
Guntur, Andhra Pradesh, India
NIZAM'S Institute of Medical Sciences
Hyderabad, Andhra Pradesh, India
Sunrise Hospital
Vijayawada, Andhra Pradesh, India
Lifecare Hospital and Research Centre
Bengaluru, Karnataka, India
Seth GS Medical College & KEM Hospital
Mumbai, Maharashtra, India
King Edward Memorial Hospital
Pune- Maharashtra, Maharashtra, India
Maulana Azad Medical College
Delhi, New Delhi, India
Madras Diabetes Research Foundation
Chennai, Tamil Nadu, India
Shri Mahant Indiresh Hospital
Dehradun, Uttarakhand, India
Seino Internal Medicine Clinic_Internal medicine
Koriyama-shi, Fukushima, Japan, Japan
Nippon Kokan Fukuyama Hospital_Diabetology
Fukuyama-shi, Hiroshima, , Japan
Sasaki Internal Medicine
Hokkaido, , Japan
Nishiyamado Keiwa Hospital_Internal Medicine
Ibaraki, , Japan
Kanno Naika_Internal Medicine
Mitaka-shi, Tokyo, , Japan
Minami Akatsuka Clinic
Mito-shi, Ibaraki, , Japan
Tokyo-Eki Center-building Clinic_Internal Medicine
Tokyo, , Japan
Fukuwa Clinic_Internal Medicine
Tokyo, , Japan
Fukuwa Clinic
Tokyo, , Japan
Osteo Medic s.c. Artur Racewicz Jerzy Supronik
Bialystok, Podlaskie Voivodeship, Poland
NZOZ Specjalistyczny Osrodek Internistyczno-Diabetologiczny Małgorzata Arciszewska
Bialystok, Podlaskie Voivodeship, Poland
Kresmed Sp. z o. o.
Bialystok, Podlaskie Voivodeship, Poland
M2M Med. Sp. z o.o. Sp. j.
Chorzów, Silesian Voivodeship, Poland
M2M Med. Sp. z o.o. Sp. j.
Chorzów, , Poland
Pratia S.A.
Gdynia, , Poland
Pratia S.A.
Katowice, , Poland
Gabinet Lekarski Malgorzata Saryusz-Wolska
Lodz, , Poland
Etyka Osrodek Badan Klinicznych Tomasz Pesta S.K.A.
Olsztyn, , Poland
Gaja Poradnie Lekarskie
Poznan, , Poland
Panstwowy Instytut Medyczny Ministerstwa Spraw Wewnetrznych I Administracji
Warsaw, , Poland
Centrum Medyczne Oporow
Wroclaw, , Poland
Samodzielny Publiczny Szpital Kliniczny Nr 1 im. Prof. Szyszko
Zabrze, , Poland
KARDIO-SANUS, spol. s r.o.
Bratislava, , Slovakia
MEDISPEKTRUM s.r.o.
Bratislava, , Slovakia
HUMAN-CARE, s.r.o.
Košice, , Slovakia
Univerzitna nemocnica L. Pasteura Kosice
Košice, , Slovakia
Vysokospecializovany odborny ustav geriatricky sv. Lukasa v Kosiciach, n.o.
Košice, , Slovakia
Tatratrial s.r.o.
Rožňava, , Slovakia
Hospital Universitario Puerta de Hierro Majadahonda
Majadahonda, Madrid, Spain
Hospital Fundación Alcorcón
Alcorcón, , Spain
Hospital Vall d'Hebron
Barcelona, , Spain
Hospital de Bellvitge
L'Hospitalet de Llobregat, , Spain
Hospital Gregorio Marañón
Madrid, , Spain
Hospital Universitario de Canarias
Santa Cruz de Tenerife, , Spain
Hospital Clinico Universitario de Valencia
Valencia, , Spain
Siriraj Hospital
Bangkok Noi, Bangkok, Thailand
Thammasat Hospital
Klong Luang Pathum Thani, Changwat Pathum Thani, Thailand
Thammasat University Hospital
Klong Luang, Changwat Pathum Thani, Thailand
Maharaj Nakorn Chiang Mai Hospital
Chiang Mai, Mueang Chiang Mai, Thailand
King Chulalongkorn Memorial Hospital
Bangkok, , Thailand
Phramongkutklao Hospital
Bangkok, , Thailand
Siriraj Hospital
Bangkok, , Thailand
Countries
Review the countries where the study has at least one active or historical site.
Other Identifiers
Review additional registry numbers or institutional identifiers associated with this trial.
U1111-1291-5907
Identifier Type: OTHER
Identifier Source: secondary_id
2023-505857-42
Identifier Type: EUDRACT_NUMBER
Identifier Source: secondary_id
NN9388-7700
Identifier Type: -
Identifier Source: org_study_id
More Related Trials
Additional clinical trials that may be relevant based on similarity analysis.